Filter results
You can narrow down the results using the filters
Audience
Topics
Our work
Diseases
Year
117 results
-
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 25 July 2025
Life Saving Drugs Program (LSDP) Expert Panel (the panel) agenda for the 17th meeting on 25 July 2025. -
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 6 March 2025
Life Saving Drugs Program (LSDP) Expert Panel (the panel) agenda for the 17th meeting on 6 March 2025. -
Avalglucosidase alfa Terms of Reference and Protocol Questions
This report outlines the Avalglucosidase alfa 24 Month Review Terms of Reference and Protocol Questions -
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 13 December 2024
Life Saving Drugs Program (LSDP) Expert Panel (the panel) agenda for the 17th meeting on 13 December 2024. -
Life Saving Drugs Program – Hereditary tyrosinaemia (type 1) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for hereditary tyrosinaemia (type 1) for the first time, or after a break. -
Life Saving Drugs Program – Pompe disease – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for Pompe disease for the first time, or after a break. -
Life Saving Drugs Program – Mucopolysaccharidosis type I (MPS I) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for MPS I for the first time, or after a break. -
Life Saving Drugs Program – Mucopolysaccharidosis type II (MPS II) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for MPS II for the first time, or after a break. -
Life Saving Drugs Program – Mucopolysaccharidosis type IVA (MPS IVA) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for MPS IVA for the first time, or after a break. -
Life Saving Drugs Program – Mucopolysaccharidosis type VI (MPS VI) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for MPS VI for the first time, or after a break. -
Life Saving Drugs Program – Gaucher disease (type 1) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Gaucher disease. -
Life Saving Drugs Program – Hereditary tyrosinaemia (type 1) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for hereditary tyrosinaemia (type 1). -
Life Saving Drugs Program – Late infantile Batten disease (CLN2 disease) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Batten disease. -
Life Saving Drugs Program – Pompe disease – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Pompe disease. -
Life Saving Drugs Program – Mucopolysaccharidosis type I (MPS I) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS I. -
Life Saving Drugs Program – Mucopolysaccharidosis type II (MPS II) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS II. -
Life Saving Drugs Program – Mucopolysaccharidosis type IVA (MPS IVA) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS IVA. -
Life Saving Drugs Program – Mucopolysaccharidosis type VI (MPS VI) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS VI. -
Life Saving Drugs Program – Gaucher disease (type 1) – Patient test results spreadsheet
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program. -
Life Saving Drugs Program – Hereditary tyrosinaemia (type 1) – Patient test results spreadsheet
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program. -
Life Saving Drugs Program – Late-Infantile Onset Batten disease (CLN2 disease) – Patient test results spreadsheet
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program. -
Life Saving Drugs Program – Pompe disease – Patient test results spreadsheets
Treating physicians use the relevant spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program. -
Life Saving Drugs Program – Mucopolysaccharidosis type I (MPS I) – Patient test results spreadsheet
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program. -
Life Saving Drugs Program – Mucopolysaccharidosis type II (MPS II) – Patient test results spreadsheet
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program. -
Life Saving Drugs Program – Mucopolysaccharidosis type IVA (MPS IVA) – Patient test results spreadsheet
Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.